CN101879295A - Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis - Google Patents
Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis Download PDFInfo
- Publication number
- CN101879295A CN101879295A CN 201010201160 CN201010201160A CN101879295A CN 101879295 A CN101879295 A CN 101879295A CN 201010201160 CN201010201160 CN 201010201160 CN 201010201160 A CN201010201160 A CN 201010201160A CN 101879295 A CN101879295 A CN 101879295A
- Authority
- CN
- China
- Prior art keywords
- psoriasis
- minutes
- branch
- blood stasis
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis. Aiming at the pathogeny of forming psoriasis, namely obstruction in channels and collaterals and qi and blood stagnation, the Chinese medicinal psoriasis-eliminating decoction for treating the blood stasis type psoriasis is prepared from natural Chinese medicinal herbs such as lightyellow sophora root, belvedere fruit, peach seed, red paeony root, safflower, root of red-rooted salvia, Chinese angelica, suberect spatholobus stem, common burreed rhizome, zedoary and densefruit pittany root-bark which have the effects of invigorating blood circulation and removing blood stasis and nourishing blood to expel wind through a scientific formula. Through clinical trials, the Chinese medicinal psoriasis-eliminating decoction has the advantages of good treatment effect, 94.5 percent of effective rate, low treatment cost and no side effect, and is worthy of clinical popularization.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, relate in particular to the psoriatic Chinese medicine decoction of a kind of treatment blood stasis type.
Background technology
Psoriasis is chronic, recurrent, inflammatory skin disease, is that a kind of cause of disease is not bright, and the pathogenesis complexity does not still have the common skin diseases of specific treatment method, is a kind of typical somatopsychic illness.Western medical treatment mainly is at certain part in the numerous morbidity links of psoriasis at present, and certain toxic and side effects arranged all, the psoriatic medicine of Chinese traditional treatment is more, but be mostly based on oral, the problem that all has therapeutic effect, simultaneously, not only financial burden is heavy, bigger to the patient body health effect again for oral drugs.
Summary of the invention
Motherland's medical science thinks that meridians intercept, and coagulation of QI-blood is the psoriatic cause of disease, and activating blood circulation to dissipate blood stasis, nourishing blood to expel wind are the Therapeutic Principle of primary disease.To this, the objective of the invention is selected natural Chinese medicinal herb with activating blood circulation to dissipate blood stasis, nourishing blood to expel wind, through scientific composition, make the psoriatic Chinese medicine Xiaoyin of a kind of treatment blood stasis type soup.
The objective of the invention is to be achieved through the following technical solutions, the psoriatic Chinese medicine Xiaoyin of this treatment blood stasis type soup is made up of the raw material of Chinese medicine of following weight fraction: Radix Sophorae Flavescentis 25-35 branch, Fructus Kochiae 10-20 branch, Semen Persicae 15-25 branch, Radix Paeoniae Rubra 10-20 branch, Flos Carthami 25-35 branch, Radix Salviae Miltiorrhizae 10-20 branch, Radix Angelicae Sinensis 10-20 branch, Caulis Spatholobi 25-35 branch, rhizoma sparganic 6-12 branch, Rhizoma Curcumae 6-12 branch, Cortex Dictamni 25-35 branch.
The raw material of Chinese medicine that the psoriatic Chinese medicine Xiaoyin of this treatment blood stasis type soup is divided by following optimum weight is formed: Radix Sophorae Flavescentis 30 minutes, the Fructus Kochiae 15 minutes, Semen Persicae 20 minutes, Radix Paeoniae Rubra 15 minutes, Flos Carthami 30 minutes, Radix Salviae Miltiorrhizae 15 minutes, Radix Angelicae Sinensis 15 minutes, Caulis Spatholobi 30 minutes, rhizoma sparganic 9 minutes, Rhizoma Curcumae 9 minutes, Cortex Dictamni 30 minutes.
The preparation method of Chinese medicine Xiaoyin soup of the present invention: take by weighing Radix Sophorae Flavescentis, the Fructus Kochiae, Semen Persicae, Radix Paeoniae Rubra, Flos Carthami, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, Caulis Spatholobi, rhizoma sparganic, Rhizoma Curcumae, Cortex Dictamni respectively in above ratio, the water that adds 10 times of amounts of raw material of Chinese medicine soaks decocting liquid 1000ml.
In the prescription, with Radix Sophorae Flavescentis, the Fructus Kochiae, Cortex Dictamni clearing away heat-damp and promoting diuresis, in the time of dispelling wind for relieving itching, with blood circulation promoting and blood stasis dispelling, auxilliary Radix Salviae Miltiorrhizae, Chinese angelica blood supplementing nourish blood with Semen Persicae, Radix Paeoniae Rubra, Flos Carthami, Caulis Spatholobi, clearing away heart-fire for tranquillization, and add with rhizoma sparganic, Rhizoma Curcumae with removing blood stasis; All medicines share, and gather the effect of activating blood circulation to dissipate blood stasis, blood-supplementing blood-nourishing, dispelling wind for relieving itching, clearing away heat-damp and promoting diuresis altogether.
Clinical data
1, physical data
218 routine patients are my section's inpatient.The case selected condition: 1. meet the diagnostic criteria of psoriasis vulgaris (carrying out phase/resting stage) clinically, other organic diseases except the routine examination are admitted to hospital and are not used glucocorticoid, immunosuppressant in preceding 1 month, do not use retinoic acid in 3 months; 2. case exclusion standard: be associated with viscera disease patients such as severe cardiac, brain, liver, kidney; Trimester of pregnancy, women breast-feeding their children, not in accordance with regulations or mismatch to detect and affect the treatment and safety judgement person with further consultation regularly.Above-mentioned case is divided into treatment group and each 109 example of matched group at random.Two groups of patients made in year, aspect the sex, the distribution of course of disease length and patient's clinical classification aspect, all showed no significant difference, had comparability.See Table 1-4.
Table 1 patient age distribution table (year)
Two groups of age ratios are than P＞0.05, and no significant difference has comparability.
Table 2 patient sex distribution table
Two groups of sex ratios show no significant difference than P＞0.05, have comparability.
Table 3 patient course of disease distribution table (year)
Two groups of patient's courses of disease compare P＞0.05, show no significant difference, have comparability.
Table 4 patient clinical classification
Two groups show no significant difference, have comparability.
The statistical method data is represented with mean ± standard deviation, adopts X 2 test to carry out statistical analysis.
2, Therapeutic Method
The treatment group adopts JS809-B intelligence Chinese medicine vapour to treat instrument stifling (the modern strong medical apparatus and instruments company limited in Guangzhou produces), is the closed herb steam therapy of single seat.Get Xiaoyin soup immersion decocting liquid 1000ml of the present invention and put into vapour treatment instrument medicine-chest, energized, intelligent keyboard control middle water level, temperature transfers to 41-42 ℃, and the time is provided with 20 minutes.Need not wash after stifling, external in evening 0.025% tretinoin ointment, once a day or the next day once, 10 times is a course of treatment.Matched group evening, be a course of treatment twice, 10 day every day with 0.025% tretinoin ointment.
3, PASI standards of grading
Psoriatic lesion area standards of grading
| Mark | ??0 | ??1 | ??2 | ??3 | ??4 | ??5 | ??6 |
| Skin lesion area (%) | ??0 | ??＜10 | ??10～29 | ??30～49 | ??50～69 | ??70～89 | ??90～100 |
Psoriasis severity scale standard
| The mark clinical manifestation | ??0 | ??1 | ??2 | ??3 | ??4 |
| Erythema | Do not have | Kermesinus | Little red | Pale red | Cerise |
| The plump infiltration | Do not have | Not obvious a little more than the surface outward appearance | It is obvious to be higher than surface, and degree is hard among touching | It is obvious to be higher than surface, plumpness | The severe plumpness |
| Squama | Do not have | Outward appearance slightly, a little is thin not obvious | Outward appearance is obvious, and is thinner | Outward appearance clearly, and is thicker, in the form of sheets | Thick, to pile up, squama comes off when undressing |
4, PASI methods of marking:
This method is divided into four parts with human body: head and neck, trunk, upper limb, lower limb, calculate the skin lesion area by table earlier, calculate erythra squama D respectively by table again, soak into I and erythema E, be multiplied by coefficient separately after the addition, whole body four parts (head and neck, trunk, upper limb, lower limb) score addition, just draw the PASI total points at last.
PASI total points=head area integral * head severity scale (D+I+E) * 0.1+ upper limb area integral * upper limb severity scale (D+I+E) * 0.2+ trunk area integral * trunk severity scale (D+I+E) * 0.3+ lower limb area integral * severe lower extremity degree scoring (D+I+E) * 0.4.
Follow up a case by regular visits to the recurrence situation: with telephone counseling with come the mode of institute check that the case of clinical cure is followed up a case by regular visits to.
5, therapeutic evaluation index
PASI value * 100% clinical recovery before therapeutic index=(PASI value one treatment back PASI value before the treatment)/treatment: therapeutic index 〉=90%
Produce effects: 60%≤therapeutic index＜90%
Progressive: 20%≤therapeutic index＜60%
Invalid: therapeutic index＜20%
Effective percentage=(the routine number of fully recovering+produce effects example number)/qualified case load * 100%
6, therapeutic outcome
(1) efficacy assessment standard: PASI value * 100% before therapeutic index=(PASI value before the treatment-treatment back PASI value)/treatment.Clinical recovery: therapeutic index 〉=90%, produce effects: 60%≤therapeutic index＜90%; Effectively: 20%≤therapeutic index＜60%; Invalid: therapeutic index＜20%.Effective percentage=(treating routine number+produce effects example number)/meet case load * 100%.
Relatively seeing the following form of (2) two groups of curative effects
Two groups of curative effects relatively
Two groups of total effective rates compare, P＜0.05, and treatment group curative effect is better than matched group
Follow up a case by regular visits to relapse rate and relatively see the following form for (3) two groups
Follow up a case by regular visits to relapse rate relatively for two groups
Two groups of patients follow up a case by regular visits to relapse rate relatively, p＜0.05, and the treatment group obviously is better than matched group, has comparability.
Model case
Case 1: Huang, man, 41 years old, cadre, Mining Group Bao Dian colliery, Yanzhou.Cover squama outward because of the trunk extremity play speckle shape skin lesion, showed effect repeatedly 24 years, come institute to go to a doctor in 2006 moons 23 year.The finding of having a medical check-up: trunk extremity skin lesion is the speckle shape, the skin lesion plumpness, and long-pending after the squama, the substrate color is darker, and dimly red tongue has ecchymosis.Through above-mentioned two course of therapy, skin lesion disappears, and follows up a case by regular visits to and does not have the recurrence of opinion half a year.
Case 2: paddy, the man, 50 years old, the workman, new river in Shangdong Province Mining Group, the general method of the whole body companion of red class desilverization white squama 15 years comes institute to go to a doctor on April 4th, 2005.The finding of having a medical check-up: general skin lesion of trunk extremity, xerosis cutis, skin lesion is thicker, and squama is more, and part is seen and is chapped companion's scratch, pale tongue with thin fur.Treated for 3 courses of treatment through said method, skin lesion disappears, and follows up a case by regular visits to and does not have recurrence half a year.
The specific embodiment
Embodiment one: take by weighing Radix Sophorae Flavescentis 30g, Fructus Kochiae 15g, Semen Persicae 20g, Radix Paeoniae Rubra 15g, Flos Carthami 30g, Radix Salviae Miltiorrhizae 15g, Radix Angelicae Sinensis 15g, Caulis Spatholobi 30g, rhizoma sparganic 9g, Rhizoma Curcumae 9g, Cortex Dictamni 30g respectively.The water that adds 10 times of amounts of raw material of Chinese medicine soaks decocting liquid 1000ml.
Embodiment two: take by weighing Radix Sophorae Flavescentis 25g, Fructus Kochiae 20g, Semen Persicae 15g, Radix Paeoniae Rubra 20g, Flos Carthami 25g, Radix Salviae Miltiorrhizae 20g, Radix Angelicae Sinensis 10g, Caulis Spatholobi 35g, rhizoma sparganic 6g, Rhizoma Curcumae 12g, Cortex Dictamni 35g respectively.The water that adds 10 times of amounts of raw material of Chinese medicine soaks decocting liquid 1000ml.
Embodiment three: take by weighing Radix Sophorae Flavescentis 35g, Fructus Kochiae 10g, Semen Persicae 25g, Radix Paeoniae Rubra 10g, Flos Carthami 35g, Radix Salviae Miltiorrhizae 10g, Radix Angelicae Sinensis 20g, Caulis Spatholobi 25g, rhizoma sparganic 12g, Rhizoma Curcumae 6g, Cortex Dictamni 25g respectively.The water that adds 10 times of amounts of raw material of Chinese medicine soaks decocting liquid 1000ml.
Claims (2)
1. treatment blood stasis type psoriatic Chinese medicine Xiaoyin soup is characterized in that the psoriatic Chinese medicine Xiaoyin of this treatment blood stasis type soup is made up of the raw material of Chinese medicine of following weight fraction: Radix Sophorae Flavescentis 25-35 branch, Fructus Kochiae 10-20 branch, Semen Persicae 15-25 branch, Radix Paeoniae Rubra 10-20 branch, Flos Carthami 25-35 branch, Radix Salviae Miltiorrhizae 10-20 branch, Radix Angelicae Sinensis 10-20 branch, Caulis Spatholobi 25-35 branch, rhizoma sparganic 6-12 branch, Rhizoma Curcumae 6-12 branch, Cortex Dictamni 25-35 branch.
2. the psoriatic Chinese medicine Xiaoyin of a kind of treatment blood stasis type according to claim 1 soup is characterized in that the raw material of Chinese medicine that the psoriatic Chinese medicine Xiaoyin of this treatment blood stasis type soup is divided by following optimum weight forms: Radix Sophorae Flavescentis 30 minutes, the Fructus Kochiae 15 minutes, Semen Persicae 20 minutes, Radix Paeoniae Rubra 15 minutes, Flos Carthami 30 minutes, Radix Salviae Miltiorrhizae 15 minutes, Radix Angelicae Sinensis 15 minutes, Caulis Spatholobi 30 minutes, rhizoma sparganic 9 minutes, Rhizoma Curcumae 9 minutes, Cortex Dictamni 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102011604A CN101879295B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102011604A CN101879295B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101879295A true CN101879295A (en) | 2010-11-10 |
| CN101879295B CN101879295B (en) | 2012-04-11 |
Family
ID=43051524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102011604A Expired - Fee Related CN101879295B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101879295B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102205089A (en) * | 2010-08-06 | 2011-10-05 | 朱五元 | Medicine for treating psoriasis |
| CN103211899A (en) * | 2012-11-02 | 2013-07-24 | 魏晓文 | Method for treating psoriasis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637585A (en) * | 2009-08-20 | 2010-02-03 | 卢速江 | Chinese herbal preparation for treating posirasis and preparation method thereof |
-
2010
- 2010-06-03 CN CN2010102011604A patent/CN101879295B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101637585A (en) * | 2009-08-20 | 2010-02-03 | 卢速江 | Chinese herbal preparation for treating posirasis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《时珍国医国药》 20041231 罗清 中医药治疗银屑病近况 871-872 1-2 第15卷, 第7期 2 * |
| 《河北中医》 20040731 黄清平 寻常型银屑病的中医治疗概况 547-549 1-2 第26卷, 第7期 2 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102205089A (en) * | 2010-08-06 | 2011-10-05 | 朱五元 | Medicine for treating psoriasis |
| CN102205089B (en) * | 2010-08-06 | 2012-08-15 | 朱五元 | Medicine for treating psoriasis |
| CN103211899A (en) * | 2012-11-02 | 2013-07-24 | 魏晓文 | Method for treating psoriasis |
| CN103211899B (en) * | 2012-11-02 | 2014-07-16 | 魏晓文 | Method for treating psoriasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101879295B (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105147811B (en) | A kind of external medicine composition and preparation method thereof for preventing and treating hand-foot syndrome | |
| CN105535694A (en) | Traditional Chinese medicine composition for treating hyperuricemia | |
| CN104587442A (en) | Foot bath traditional Chinese medicine composition for treating wind-cold-dampness arthralgia and application of foot bath traditional Chinese medicine composition | |
| CN102526611B (en) | Chinese medicinal composition for treating chronic heart failure | |
| CN101879295B (en) | Chinese medicinal psoriasis-eliminating decoction for treating blood stasis type psoriasis | |
| CN100381155C (en) | Medicine for treating mammary glands hyperplasia | |
| CN103055069B (en) | External Chinese medicine composition for treating postherpetic neuralgia and preparation method of composition | |
| CN103446575A (en) | Medicine for treating gout | |
| CN103099882A (en) | Traditional Chinese medicine composition for treating liver qi-stagnation type hyperplasia of mammary glands | |
| Han et al. | Tuina along the meridians combined with Chinese medicine for motor functions and activities of daily living in patients with post-stroke upper limb spasticity | |
| CN103536842A (en) | Mixture for treating psoriasis | |
| CN1181835C (en) | Chinese medicine preparation for treating rheumatism and rheumatoid disease | |
| CN105833059A (en) | Chinese medicinal composition for treating psoriasis | |
| CN104940712A (en) | Traditional Chinese medicine preparation for treating arteriosclerosis | |
| CN104940842A (en) | Traditional Chinese medicine combination for treating cerebral edema | |
| CN104147463B (en) | A kind of medicine for treating psoriasis | |
| CN105434986A (en) | Traditional Chinese medicine preparation used for treating arthralgia | |
| CN105456559A (en) | Chinese herbal medicine compound preparation for treating Qi-stagnation and blood stasis type chronic cholecystitis | |
| CN104225435A (en) | Traditional Chinese medicine preparation for treating turbid phlegm obstructing type coronary heart disease | |
| CN104771580A (en) | Traditional Chinese medicine composition for treating prostatitis | |
| CN103550469A (en) | Traditional Chinese medicine composition for treating lumbago symptoms | |
| CN103239557B (en) | Medicament for treating chronic eczema and production method of medicament | |
| CN104587077A (en) | Traditional Chinese medicine composition for treating vitiligo antigens | |
| CN104435309A (en) | Traditional Chinese medicine composition for treating costal chondritis and preparation method thereof | |
| CN104056133A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120411 Termination date: 20130603 |